IMPACT OF NIRSEVIMAB ON RESPIRATORY SYNCYTIAL VIRUS BRONCHIOLITIS IN HOSPITALIZED INFANTS: A REAL-WORLD STUDY.

Regarding nirsevimab immunization status, among 1085 infants hospitalized for bronchiolitis, the odds of hospitalization for respiratory syncytial virus bronchiolitis were 4.7 times higher for nonimmunized children. Immunized infants were less likely to require oxygen supplementation (20.